SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthen ...

ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, ...

SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of A ...

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of ...

Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were observed in patients titrated to the highest dose SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neuro ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Core Insights - Artelo Biosciences, Inc. announced new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol and tetramethylpyrazine, showing significant improvements over conventional CBD in treating stress-induced depression and anxiety [1][2][4] Group 1: Study Findings - The peer-reviewed study demonstrated that ART12.11 significantly outperformed CBD alone in reducing symptoms of stress-induced depression and anxiety, while also achieving superior oral bioavailability [2][4] - ART12.11 reversed stress-induced behavioral deficits and produced robust anti-depressant and anxiolytic-like effects, superior to CBD alone, TMP alone, or a non-crystalline mixture of CBD and TMP [7] - Mechanistic insights revealed that ART12.11 enhances activation of endocannabinoid and serotonergic systems in brain regions critical to mood regulation, suggesting a selective influence that maximizes therapeutic benefits while minimizing side effects [5][7] Group 2: Regulatory and Developmental Aspects - The UK regulatory authority, MHRA, has agreed that Artelo may rely on existing nonclinical and clinical evidence for CBD and leverage legacy data for TMP, which is expected to streamline the development plan for ART12.11 [5][6] - The guidance from MHRA is anticipated to reduce costs and enable rapid advancement towards the proposed first human study with ART12.11 planned for next year [5][6] Group 3: Company Overview - Artelo Biosciences is focused on developing proprietary therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions [8] - The company has adopted a digital asset treasury strategy, designating Solana as a core reserve asset to enhance liquidity management and long-term value creation [8]

Core Viewpoint - Artelo Biosciences, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on lipid-signaling pathways for various medical conditions [1][2]. Group 1: Offering Details - The company offered 640,924 shares of common stock at a public price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The gross proceeds from the offering were approximately $3.0 million before deducting underwriting discounts and other expenses [2]. - Underwriters were granted a 45-day option to purchase an additional 102,272 shares at the public offering price to cover over-allotments [2]. Group 2: Regulatory and Documentation - The shares and warrants were offered under a "shelf" registration statement on Form S-3, which was filed with the SEC on July 6, 2023, and declared effective on July 14, 2023 [3]. - The final prospectus supplement and accompanying base prospectus were filed with the SEC on September 5, 2025, and are available on the SEC's website [4]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing significant unmet needs in various medical conditions including cancer and pain [7]. - The company has adopted a corporate finance initiative to deploy excess capital into digital assets as part of its treasury strategy [7].

Company Performance - Neonode Inc. experienced a stock price drop of approximately 68.34%, closing at $6.81, down from a year high of $29.9, influenced by market reactions to company developments and industry trends [2][8] - Artelo Biosciences saw a 50.34% decrease in its stock price, closing at $4.35, amid ongoing clinical trials and a public offering priced at $3 million [3][8] - 707 Cayman Holdings Limited faced a 48.45% decline in its stock price to $0.39, potentially due to challenges in the retail sector and exploring a crypto treasury reserve with Precious Choice Global Limited [4][8] - Aethlon Medical's stock price fell by 45.76% to $0.73, possibly linked to recent performance updates and investor sentiment towards the healthcare sector, with a public offering valued at $4.5 million [5] - Purple Biotech's stock price decreased by 43.54%, closing at $0.80, which may be related to clinical trial results and market conditions affecting biotech firms [6] Market Trends - The significant price movements of these companies highlight the importance of monitoring market trends, company developments, and broader economic factors that can impact stock performance [7]

Core Viewpoint - Artelo Biosciences, Inc. has announced a public offering of common stock and pre-funded warrants, aiming to raise approximately $3.0 million to support its clinical-stage pharmaceutical initiatives focused on treating various medical conditions [1][6]. Group 1: Offering Details - The company is offering 640,924 shares of common stock at a price of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at a price of $4.399 per warrant [1]. - The total gross proceeds from the offering are expected to be around $3.0 million before deducting underwriting discounts and other expenses [1]. - Underwriters have a 45-day option to purchase an additional 102,272 shares to cover over-allotments [1]. Group 2: Underwriting and Registration - R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering [2]. - The shares and warrants are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on July 14, 2023 [2]. Group 3: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments that modulate lipid-signaling pathways for conditions such as cancer, pain, and dermatologic issues [6]. - The company is also implementing a digital asset treasury strategy to enhance its financial position [6].